SMTL ID : 1u8q.1

Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Peptide ELEKWAS

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.24 Å

Oligo State

hetero-oligomer

Ligands

1 x GLU- LEU- GLU- LYS- TRP- ALA- SER: GP41 PEPTIDE(Non-covalent)

GLU-LEU-GLU-LYS-TRP-ALA-SER.1: 14 residues within 4Å: Chain A: T.30, L.91, H.92, F.93, Y.94, H.96 Chain B: G.33, Y.54, D.56, D.58, R.60, R.100, R.113, V.116 19 PLIP interactions: 10 interactions with chain A, 9 interactions with chain B Hydrophobic interactions: A:F.93, B:Y.54, B:V.116 Hydrogen bonds: A:T.30, A:L.91, A:H.92, A:Y.94, A:Y.94, A:Y.94, B:D.56, B:D.58, B:R.113, B:R.113 Water bridges: A:H.92, A:H.92 Salt bridges: A:H.96, B:R.60, B:R.100, B:R.113

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Bryson, S. et al., Crystallographic definition of the epitope promiscuity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5: vaccine design implications. J.Virol. (2009)

Release Date

2004-10-05

Peptides

ANTIBODY 2F5 (LIGHT CHAIN): A
ANTIBODY 2F5 (HEAVY CHAIN): B

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

B
B

ANTIBODY 2F5 (LIGHT CHAIN)

ANTIBODY 2F5 (HEAVY CHAIN)

Related Entries With Identical Sequence